Xintela (XINT) Q2 2026 earnings summary

Executive summary

• Net sales increased to SEK 1,317 thousand in Q2 2026, up from SEK 872 thousand year-over-year, driven by the EQGen project.

• Loss before tax improved to SEK -9,762 thousand from SEK -12,119 thousand year-over-year due to higher sales and lower costs.

• XSTEM achieved its primary safety objective in a clinical study for difficult-to-heal venous leg ulcers.

• Positive results from the knee osteoarthritis study with XSTEM were published, supporting disease-modifying effects.

• SEK 30 million convertible loan secured from principal shareholder to accelerate XSTEM development and repay previous debt.

Financial highlights

• Net sales for Q2 2026: SEK 1,317 thousand (Q2 2025: SEK 872 thousand).

• Loss before tax for Q2 2026: SEK -9,762 thousand (Q2 2025: SEK -12,119 thousand).

• Loss per share for Q2 2026: SEK -0.01 (Q2 2025: SEK -0.02).

• Cash and cash equivalents at June 30, 2026: SEK 30,724 thousand (June 30, 2025: SEK 10,532 thousand).

• Operating loss for Q2 2026: SEK -9,683 thousand (Q2 2025: SEK -11,526 thousand).

Outlook and guidance

• Focus on accelerating XSTEM's path to market through business development and partnerships.

• Strategy includes early commercialization in select markets and ongoing efforts to secure further funding.

• Continued development of XSTEM for wound indications is planned primarily through strategic partnerships.